Oncology

Latest News

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

September 7th 2025

Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com
NOTCH1 Levels Impact Immune Response in SCLC

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe
Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

August 31st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
September 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
October 5th 2018

Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs

Jaime Rosenberg
An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the treatment was effective in disease control and most patients were satisfied with the treatment.
Site Logo
October 5th 2018

Measuring Quality of Life Among Patients With Neuroendocrine Tumors

Jaime Rosenberg
Two studies presented at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington assessed different tools for determining quality of life among patients with neuroendocrine tumors (NETs).
Preventing Antimicrobial Complications, Ensuring Stewardship in Cancer Care
October 5th 2018

Preventing Antimicrobial Complications, Ensuring Stewardship in Cancer Care

Allison Inserro
This week, infectious disease specialists from different organizations are meeting in San Francisco for ID Week, an annual conference focused on many different infectious disease topics and their intersection with cancer, HIV, respiratory diseases, and more. Two abstracts presented results about what is needed to prevent complications in cancer care, one about patients with acute myeloid leukemia (AML) with prolonged neutropenia, and one examining the frequency of antimicrobial complications following initiation of palliative chemotherapy.
Site Logo
October 4th 2018

Making the Leap to Prospective Risk in Value-Based Oncology Care

Mary Caffrey
The Institute for Value-Based Medicine travels to New York City to learn how technology and trust are key to making the leap to two-sided risk.
Site Logo
October 4th 2018

Recent Study on Site of Care Has Severe Limitations

Lucio N. Gordan, MD Debra Patt, MD
The outpatient community oncology setting is consistently less costly for cancer treatment as opposed to the outpatient hospital setting.
Site Logo
October 4th 2018

The Authors Respond and Stand Behind Their Findings

Yamini Kalidindi, MHA Jeah Jung, PhD Roger Feldman, PhD
Our study provides the first evidence on site-specific Medicare spending on chemotherapy adjusting for patient comorbid illnesses, cancer type, and other cancer-related risks.
FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma
October 3rd 2018

FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma

Laura Joszt, MA
A once-weekly dose of carfilzomib (Kyprolis) in combination with dexamethasone has been approved to treat patients with relapsed or refractory (R/R) multiple myeloma. The approved regimen improved progression-free survival and had a better overall response rate than a twice-weekly regimen.
Employers Take a Vested Interest in Healthcare
October 3rd 2018

Employers Take a Vested Interest in Healthcare

Employers may not look forward to purchasing healthcare, but they are in the position to transform the market. More employers are getting more involved in healthcare by championing alternative payment models and other services to their employees.
People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence
October 2nd 2018

People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence

Jaime Rosenberg
A new study has found that people living with HIV are at an increased risk of both first and second primary cancer incidence.
FDA Approves NGS-Based Test That Detects Very Low Levels of Cancer Cells in ALL or MM
October 2nd 2018

FDA Approves NGS-Based Test That Detects Very Low Levels of Cancer Cells in ALL or MM

Laura Joszt, MA
A test that uses next-generation sequencing (NGS) has been approved to detect and monitor minimal residual disease in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL).
Top 5 AJMC® Articles of September 2018
September 30th 2018

Top 5 AJMC® Articles of September 2018

Here are the top 5 articles for the month of September.
Working Toward CAR T-Cell Treatments With Fewer Side Effects
September 30th 2018

Working Toward CAR T-Cell Treatments With Fewer Side Effects

Mary Caffrey
Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.
Lack of Discussion Around Cancer Treatment Costs Leads to Financial Toxicity
September 29th 2018

Lack of Discussion Around Cancer Treatment Costs Leads to Financial Toxicity

Samantha DiGrande
Earlier this week, 3 studies were released that investigated the financial difficulties seen in patients living with cancer. Such difficulties are referred to as “financial toxicity,” which was studied in patients with metastatic breast cancer and older patients, as well as the conversations about cost of care that women with breast cancer have with their physicians.
Imfinzi Plus Chemotherapy Reduced Risk of Death by One-Third in Stage III NSCLC
September 28th 2018

Imfinzi Plus Chemotherapy Reduced Risk of Death by One-Third in Stage III NSCLC

Samantha DiGrande
Earlier this week, drug manufacturer Astrazeneca announced the results from a phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non­–small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy.
The Risk of Creating Healthcare Monopolies
September 26th 2018

The Risk of Creating Healthcare Monopolies

Burnout and Resilience Among Oncologists
September 26th 2018

Burnout and Resilience Among Oncologists

Healthcare Payment Models
September 26th 2018

Healthcare Payment Models

Oncology Care Within Integrated Delivery Networks
September 26th 2018

Oncology Care Within Integrated Delivery Networks

The Unique Case of the VA Model
September 26th 2018

The Unique Case of the VA Model

Best-in-Class Healthcare Delivery Models
September 26th 2018

Best-in-Class Healthcare Delivery Models

Integrated Delivery Networks
September 26th 2018

Integrated Delivery Networks

The Role of Medium-Sized Employers
September 26th 2018

The Role of Medium-Sized Employers

Large Employers and Healthcare Consolidation
September 26th 2018

Large Employers and Healthcare Consolidation

The Impact of Consolidation on Healthcare Stakeholders
September 26th 2018

The Impact of Consolidation on Healthcare Stakeholders

Potential Benefits of Healthcare Consolidation
September 26th 2018

Potential Benefits of Healthcare Consolidation

Factors Behind Healthcare Consolidation
September 26th 2018

Factors Behind Healthcare Consolidation

The Advent of Managed Care
September 26th 2018

The Advent of Managed Care

History of Mergers and Acquisitions in the Healthcare Industry
September 26th 2018

History of Mergers and Acquisitions in the Healthcare Industry

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer
September 23rd 2018

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer

Laura Joszt, MA
With cancer costs rising and patients with cancer disproportionately facing financial toxicity, alternative payment and care delivery models are thought to help alleviate some of the cost burden. However, a review finds limited evidence available to evaluate the efficacy of alternative payment and care models in cancer care.
Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News
September 22nd 2018

Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
<1
...
404142434445464748
...
188>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo